Murphy & Mullick Capital Management Corp Makes New Investment in Astera Labs, Inc. (NASDAQ:ALAB)

Murphy & Mullick Capital Management Corp acquired a new stake in Astera Labs, Inc. (NASDAQ:ALAB) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 325 shares of the company’s stock, valued at approximately $43,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ALAB. Steward Partners Investment Advisory LLC increased its position in Astera Labs by 99.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 199 shares of the company’s stock worth $26,000 after buying an additional 99 shares during the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of Astera Labs during the 4th quarter worth approximately $25,000. Kestra Investment Management LLC bought a new stake in Astera Labs in the 4th quarter valued at $28,000. GAMMA Investing LLC lifted its holdings in Astera Labs by 78.3% during the 4th quarter. GAMMA Investing LLC now owns 510 shares of the company’s stock valued at $68,000 after purchasing an additional 224 shares during the last quarter. Finally, CIBC Asset Management Inc boosted its position in Astera Labs by 5.2% during the fourth quarter. CIBC Asset Management Inc now owns 4,757 shares of the company’s stock worth $630,000 after purchasing an additional 237 shares during the period. 60.47% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, General Counsel Philip Mazzara sold 50,000 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $87.46, for a total transaction of $4,373,000.00. Following the completion of the transaction, the general counsel now directly owns 191,209 shares in the company, valued at approximately $16,723,139.14. This represents a 20.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Truett Tate sold 125,800 shares of the stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $82.53, for a total value of $10,382,274.00. Following the completion of the transaction, the chief financial officer now owns 244,242 shares of the company’s stock, valued at $20,157,292.26. The trade was a 34.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 570,990 shares of company stock worth $50,242,702 in the last three months.

Astera Labs Stock Performance

Astera Labs stock opened at $62.79 on Friday. Astera Labs, Inc. has a 52 week low of $36.22 and a 52 week high of $147.39. The stock has a market capitalization of $10.18 billion and a P/E ratio of -36.29. The stock has a fifty day moving average of $86.45 and a 200-day moving average of $89.68.

Astera Labs (NASDAQ:ALAB) last issued its earnings results on Monday, February 10th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.26 by ($0.16). Astera Labs had a negative return on equity of 10.40% and a negative net margin of 21.05%. On average, research analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ALAB shares. Stifel Nicolaus increased their target price on Astera Labs from $100.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Morgan Stanley dropped their target price on Astera Labs from $142.00 to $114.00 and set an “equal weight” rating for the company in a report on Tuesday, January 28th. Northland Securities upgraded shares of Astera Labs from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research note on Tuesday, January 28th. Raymond James assumed coverage on shares of Astera Labs in a research report on Friday, March 14th. They set an “outperform” rating and a $82.00 price target on the stock. Finally, Northland Capmk raised shares of Astera Labs from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $112.77.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.